Sclerosis multiplex (SM): vizsgálatok itt: Lengyelország
23 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Where
- Bydgoszcz, Cracow, Gdansk, Katowice, Lodz, Lublin, Nowa Sol, Olsztyn, Plewiska, Poznan, Rzeszów, Szczecin, Warsaw, Zabrze, Zory
- Életkor
- 18 év to 60 év
- People
- 705 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00 - 2. fázisTaking peopleA Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
- Where
- Gdansk, Poznan, Warsaw
- Életkor
- 10 év to 17 év
- People
- 12 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07161258 · EU 2024-519800-28-00 - 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Where
- Bydgoszcz, Cracow, Gdansk, Katowice, Lodz, Łódź, Lublin, Nowa Sol, Olsztyn, Plewiska, Poznan, Rzeszów, Szczecin, Warsaw, Zory
- Életkor
- 18 év to 60 év
- People
- 990 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00 - 2. fázisTaking peopleStudy to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasticity
- Where
- Bydgoszcz, Cracow, Katowice, Krakowie, Lodz, Oswiecim, Warsaw
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- Celgene Corp.
See details and how to join2024-517745-14-00 · EU 2024-517745-14-00 - 2/3. fázisTaking peopleStudy to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
- Where
- Gdansk, Katowice, Lodz, Poznan, Rzeszów, Warsaw
- Életkor
- 10 év to 17 év
- People
- 240 worldwide
- Run by
- TG Therapeutics, Inc.
See details and how to joinNCT07220252 · EU 2025-522257-19-00 - 2. fázisTaking peopleA Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
- Where
- Bydgoszcz, Cracow, Katowice, Kielce, Łódź, Olsztyn, Poznan, Warsaw, Zabrze
- Életkor
- 18 év to 65 év
- People
- 350 worldwide
- Run by
- TG Therapeutics, Inc.
See details and how to joinNCT07503873 · EU 2025-523757-33-00 - 3. fázisTaking peopleEfficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
- Where
- Bydgoszcz, Katowice, Plewiska k. Poznania, Rzeszow, Zabrze, Zory
- Életkor
- 18 év to 64 év
- People
- 386 worldwide
- Run by
- Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00 - 2. fázisTaking peopleA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Where
- Bydgoszcz, Gdansk, Katowice, Krakow, Lodz, Oświęcim, Słomniki, Warsaw
- Életkor
- 18 év to 70 év
- People
- 200 worldwide
- Run by
- Celgene
See details and how to joinNCT06782490 - 2. fázisTaking peopleMulticenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
- Where
- Bydgoszcz, Katowice, Kielce, Lublin, Oswiecim, Plewiska, Poznan, Szczecin, Warsaw, Wroclaw
- Életkor
- 18 év to 64 év
- People
- 230 worldwide
- Run by
- Immunic AG
See details and how to joinNCT05054140 · EU 2024-514617-35-00 - 3. fázisTaking peopleStudy to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
- Where
- Bydgoszcz, Cracow, Katowice, Kielce, Łódź, Olsztyn, Poznan, Warsaw, Zabrze, Zory
- Életkor
- 18 év to 65 év
- People
- 800 worldwide
- Run by
- TG Therapeutics, Inc.
See details and how to joinNCT05877963 · EU 2024-519284-18-00 - 3. fázisTaking peopleA Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
- Where
- Bydgoszcz, Cracow, Katowice, Kielce, Łódź, Lublin, Warsaw
- Életkor
- 18 év to 64 év
- People
- 125 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00 - 2. fázisNot yet taking people in LengyelországA Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
- Where
- Gdansk, Poznan, Warsaw
- Életkor
- 10 év to 17 év
- People
- 25 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07503340 · EU 2025-524164-37-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Where
- Bydgoszcz, Chojnice, Katowice, Krakow, Lodz, Lublin, Rzeszów, Skorzewo, Szczecin, Warsaw, Zabrze, Żory
- Életkor
- 18 év to 65 év
- People
- 1275 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07225504 - 3. fázisTaking peopleNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Where
- Bialystok, Bydgoszcz, Cracow, Katowice, Kielce, Łódź, Plewiska k. Poznania, Poznan, Rzeszow, Zabrze, Zory
- Életkor
- 18 év to 60 év
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00 - 2. fázisTaking peopleA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
- Where
- Bydgoszcz, Cracow, Gdansk, Katowice, Kielce, Krakowie, Lodz, Lublin, Poznań, Rzeszow, Rzeszów, Warsaw, Wrocław, Zabrze, Zory
- Életkor
- 18 év to 60 év
- People
- 360 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07282574 · EU 2025-521636-10-00 - 3. fázisTaking peopleEfficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
- Where
- Gdansk, Lodz, Poznan, Warsaw
- Életkor
- Up to 17 év
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-511686-11-00 · EU 2024-511686-11-00 - 3. fázisTaking peopleStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
- Where
- Poznan
- Életkor
- 10 év to 17 év
- People
- 194 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06408259 · EU 2022-501332-42-00 - 2. fázisTaking peopleA Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis
- Where
- Bydgoszcz, Katowice, Lublin, Zabrze
- Életkor
- 18 év to 64 év
- People
- 93 worldwide
- Run by
- Zenas Biopharma (USA) LLC
See details and how to join2024-512707-40-00 · EU 2024-512707-40-00 - 3. fázisTaking peopleA clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
- Where
- Bydgoszcz, Chojnice, Cracow, Katowice, Lodz, Lublin, Rzeszów, Skorzewo, Szczecin, Warsaw, Wrocław, Zabrze, Zory
- Életkor
- 18 év and over
- People
- 677 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00 - 1. fázisNot yet taking people in LengyelországA Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus
- Where
- Bydgoszcz, Cracow, Katowice, Klodzko, Lublin, Olsztyn, Skorzewo, Zabrze
- Életkor
- 18 év to 65 év
- People
- 222 worldwide
- Run by
- Polpharma Biologics International AG
See details and how to joinNCT07606521 · EU 2026-525314-61-00 - No phaseTaking peoplePolish Version Fatigue Severity Scale
- Where
- Krakow, Warsaw
- Életkor
- 18 év and over
- People
- 310
- Run by
- Jakub Antczak
See details and how to joinNCT06668649 - 3. fázisTaking peopleA Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
- Where
- Poznan
- Életkor
- 18 év to 55 év
- People
- 512
- Run by
- Celltrion
See details and how to joinNCT05906992 - 2/3. fázisTaking peopleCladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
- Where
- Warsaw
- Életkor
- 30 év to 65 év
- People
- 188
- Run by
- Institute of Psychiatry and Neurology, Warsaw
See details and how to joinNCT05961644 · EU 2024-516992-33-02